There's no greater success in biotech investing then a binary event that propels shares like a rocket. Inhibitex
Unexpectedly positive efficacy and safety results tend to do that -- especially for a drug like INX-189, which treats the large and lucrative hepatitis-C market.
This has some analysts comparing Inhibitix with Pharmasset
The danger here is if future clinical trial results don't play out as well. This happens all the time. And when a binary event goes bad, it goes really bad. Shares of Rexahn
That said, Pharmasset currently sports a market cap nearly 8 times greater than Inhibitex, post-pop. Wall Street's newest biotech darling looks to have plenty of room to run.
Keep up with the stocks mentioned in this article by tracking them in our free watchlist service, My Watchlist.